CXCR1/2 pathways in paclitaxel-induced neuropathic pain

Oncotarget

Volumn 8, Issue 14, 2017, Pages 23188-23201

  Laura, Brandolini ^a   Elisabetta, Benedetti ^b   Adelchi, Ruffini Pier ^a   Roberto, Russo ^c   Loredana, Cristiano ^b   Andrea, Antonosante ^b   Michele, d'Angelo ^b   Vanessa, Castelli ^b   Antonio, Giordano ^d,e   Marcello, Allegretti ^a   Annamaria, Cimini ^b,e,f  

^a Chemistry Section   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e TEMPLE UNIVERSITY   (United States)

^f LABORATORI NAZIONALI DEL GRAN SASSO   (Italy)

Author keywords

Chemotherapy; Chronic pain; CXCR1 2 inhibitor; IL 8; Microtubules

Indexed keywords

ALPHA TUBULIN; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CORTACTIN; FOCAL ADHESION KINASE; INTERLEUKIN 8; JANUS KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; REPARIXIN; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; PACLITAXEL;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DENSITOMETRY; DRUG EFFECT; F11 CELL; IN VIVO STUDY; MALE; NERVE CELL; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPATHIC PAIN; NEUROTOXICITY; NOCICEPTION; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN ACETYLATION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; METABOLISM; NEURALGIA; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; INTERLEUKIN-8; MALE; NEURALGIA; PACLITAXEL; RATS; RATS, WISTAR; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B;

EID: 85016986152     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15533     Document Type: Article

References (75)

1. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol. 2010; 6:657-666.
2. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014; 40:872-882.
3. Saretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014; 155:2461-2470.
4. Markman M. Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life. J Cancer Res Clin Oncol. 1996; 122:511-512.
5. Smith EM, Pang H. Therapy for chemotherapy-induced peripheral neuropathy-in reply. JAMA. 2013; 310:538.
6. Boyette-Davis J, Xin W, Zhang H, Dougherty PM. Intraepidermal nerve fiber loss corresponds to the development of taxol-induced hyperalgesia and can be prevented by treatment with minocycline. Pain. 2011; 152:308-13.
7. Burakgazi AZ, Messersmith W, Vaidya D, Hauer P, Hoke A, Polydefkis M. Longitudinal assessment of oxaliplatininduced neuropathy. Neurology. 2011; 77:980-986.
8. Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol. 2000; 424:563-576.
9. Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain. 2001; 94:293-304.
10. Zhao Y, Mu X, Du G. Microtubule-stabilizing agents: New drug discovery and cancer therapy. Pharmacol Ther. 2016; 162:134-143.
11. Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine. 2012; 59:3-9.
12. Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology. 2012; 291:1-9.
13. Zaks-Zilberman M, Zaks TZ, Vogel SN. Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine. 2001; 15:156-165.
14. Basu S, Sodhi A. Increased release of interleukin-1 and tumour necrosis factor by interleukin-2-induced lymphokine-activated killer cells in the presence of cisplatin and FK-565. Immunol Cell Biol. 1992; 70:15-24.
15. Weintraub M, Adde MA, Venzon DJ, Shad AT, Horak ID, Neely JE, Seibel NL, Gootenberg J, Arndt C, Nieder ML, Magrath IT. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol. 1996;14:935-940.
16. Ledeboer A, Jekich BM, Sloane EM, Mahoney JH, Langer SJ, Milligan ED, Martin D, Maier SF, Johnson KW, Leinwand LA, Chavez RA, Watkins LR. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun. 2007; 21:686-698.
17. Woolf CJ, Allchorne A, Safieh-Garabedian B, Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumor necrosis factor alpha. Br J Pharmacol. 1997; 121:417-424.
18. Binshtok AM, Wang H, Zimmermann K, Amaya F, Vardeh D, Shi L, Brenner GJ, Ji RR, Bean BP, Woolf CJ, Samad TA. Nociceptors are Interleukin-1 beta Sensors. J Neurosci. 2008; 28:14062-14073.
19. Ozaktay AC, Cavanaugh JM, Asik I, DeLeo JA, Weinstein JN. Dorsal root sensitivity to interleukin-1 beta, interleukin-6 and tumor necrosis factor in rats. Eur Spine J. 2002; 11:467-475.
20. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci. 2006; 27:48-55.
21. Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clinics. 2007; 45:27-37.
22. Verri Jr WA, Cunha TM, Parada CA, Poole S, Cunha FQ, Ferreira SH. Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol Ther. 2006; 112:116-138.
23. Uçeyler N, Kafke W, Riediger N, He L, Necula G, Toyka KV, Sommer C. Elevated proinflammatory cytokine expression in affected skin in small fiber neuropathy. Neurology. 2010; 74:1806-1813.
24. Bertini R, Allegretti M, Bizzarri C, Moriconi A, Locati M, Zampella G, Cervellera MN, Di Cioccio V, Cesta MC, Galliera E, Martinez FO, Di Bitondo R, Troiani G, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA. 2004; 101:11791-11796.
25. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum D, Guan JL, Dontu G, Wicha MS. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010; 120:485-97.
26. Brandolini L, Cristiano L, Fidoamore A, De Pizzol M, Di Giacomo E, Florio TM, Confalone G, Galante A, Cinque B, Benedetti E, Ruffini PA, Cifone MG, Giordano A, et al. Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling. Oncotarget. 2015; 6:43375-94. doi: 10.18632/oncotarget.6234.
27. Schott A.F, Wicha MS, Perez R, Kato G, Avery T, Cristofanilli M, Reuben JM, Alpaugh RK, McCanna S, Ruffini PA, Goldstein LJ. A phase Ib study of the CXCR1/2 inhibitor reparixin in combination with weekly paclitaxel in metastatic HER2 negative breast cancer -Final analysis. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2015 abstract C22 Mol Cancer Ther. 2015; 14.
28. Canta A, Chiorazzi A, Cavaletti G. Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem. 2009; 16:1315-1324.
29. Xue ZJ, Shen L, Wang ZY, Hui SY, Huang YG, Ma C. STAT3 inhibitor WP1066 as a novel therapeutic agent for bCCI neuropathic pain rats. Brain Res. 2014; 1583:79-88.
30. Nicolas CS, Amici M, Bortolotto ZA, Doherty A, Csaba Z, Fafouri A, Dournaud P, Gressens P, Collingridge GL, Peineau S. The role of JAK-STAT signaling within the CNS. JAKSTAT. 2013; 2:e22925.
31. Benbow SJ, Cook BM, Reifert J, Wozniak KM, Slusher BS, Littlefield BA, Wilson L, Jordan MA, Feinstein SC. Effects of Paclitaxel and Eribulin in Mouse Sciatic Nerve: A Microtubule-Based Rationale for the Differential Induction of Chemotherapy-Induced Peripheral Neuropathy. Neurotox Res. 2016; 29:299-313.
32. Derry WB, Wilson L, Jordan MA. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry. 1995; 34:2203-2211.
33. Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: occurrence and management approach. Clin Breast Cancer. 2011; 11:73-81.
34. Morfini GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, Brown RH Jr, Brown H, Tiwari A, Hayward L, Edgar J, Nave KA, Garberrn J, et al. Axonal transport defects in neurodegenerative diseases. J Neurosci. 2009; 29:12776-12786.
35. Horie H, Takenaka T, Ito S, Kim SU. Taxol counteracts colchicine blockade of axonal transport in neurites of cultured dorsal root ganglion cells. Brain Res 1987; 420:144-146.
36. Archer DR, Dahlin LB, McLean WG. Changes in slow axonal transport of tubulin induced by local application of colchicine to rabbit vagus nerve. Acta Physiol Scand. 1994; 150:57-65.
37. Dahlstrom A. Effect of colchicine on transport of amine storage granules in sympathetic nerve of rat. Eur J Pharmacol. 1968; 5:111-113.
38. Younger DS, Mayer SA, Weimer LH, Alderson LM, Seplowitz AH, Lovelace RE. Colchicine induced myopathy and neuropathy. Neurology. 1991; 41:943-944.
39. Vichaya EG, Chiu GS, Krukowski K, Lacourt TE, Kavelaars A, Dantzer R, Heijnen CJ, Walker AK., Mechanisms of chemotherapy-induced behavioral toxicities. Front Neurosci. 2015; 9:131.
40. Vendrell I, Macedo D, Alho I, Dionísio MR, Costa L. Treatment of Cancer Pain by Targeting Cytokines. Mediators Inflamm. 2015; 984570.
41. Mangiacavalli S, Corso A, De Amici M, Varettoni M, Alfonsi E, Lozza A, Lazzarino M. Emergent T-helper2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain. Br J Haematol. 2010; 149:916-918.
42. Schafers M, Sorkin L. Effect of cytokines on neuronal excitability. Neurosci Lett. 2008; 437:188-193.
43. Alé A, Bruna J, Morell M, van de Velde H, Monbaliu J, Navarro X, Udina E. Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model. Exp Neurol. 2014; 253:165-173.
44. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annual Review of Immunology. 2014; 32:659-702.
45. White FA, Wilson NM. Chemokines as pain mediators and modulators. Curr Opin Anaesthesiol. 2008; 21:580-585.
46. Cunha TM, Barsante MM, Guerrero AT, Verri WA Jr, Ferreira SH, Coelho FM, Bertini R, Di Giacinto C, Allegretti M, Cunha FQ, Teixeira MM. Treatment with DF 2162, a noncompetitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice. Br J Pharmacol. 2008; 154:460-470.
47. Kim SJ, Park SM, Cho YW, Jung YJ, Lee DG, Jang SH, Park HW, Hwang SJ, Ahn SH. Changes in expression of mRNA for interleukin-8 and effects of interleukin-8 receptor inhibitor in the spinal dorsal horn in a rat model of lumbar disc herniation. Spine (Phila Pa 1976) 2011; 36:2139-2146.
48. Geraldo S, Khanzada UK, Parsons M, Chilton JK, Gordon-Weeks PR. Targeting of the F-actin-binding protein drebrin by the microtubule plus-tip protein EB3 is required for neuritogenesis. Nat Cell Biol. 2008; 10:1181-1189.
49. Gu C, Zhou W, Puthenveedu MA, Xu M, Jan YN, Jan LY. The microtubule plus-end tracking protein EB1 is required for Kv1 voltage-gated K+ channel axonal targeting. Neuron. 2006; 52:803-816.
50. Jaworski, J, Kapitein LC, Gouveia SM, Dortland BR, Wulf PS, Grigoriev I, Camera P, Spangler SA, Di Stefano P, Demmers J, Krugers H, Defilippi P, Akhmanova A, et al. Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity. Neuron. 2006; 61:85-100.
51. Palazzo AF, Eng CH, Schlaepfer DD, Marcantonio EE, Gundersen GG. Localized stabilization of microtubules by integrin-and FAK-facilitated Rho signaling. Science. 2004; 303:836-839.
52. Koch N, Kobler O, Thomas U, Qualmann B, Kessels MM. Terminal axonal arborization and synaptic bouton formation critically rely on abp1 and the arp2/3 complex. PLoS One. 2014; 9:e97692.
53. Mierke CT. The role of focal adhesion kinase in the regulation of cellular mechanical properties. Phys Biol. 2013; 10:065005.
54. Schaller MD. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci. 2010; 123:1007-1013.
55. Guan JL, Shalloway D. Regulation of focal adhesionassociated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature. 1992; 358:690-692.
56. Tancioni I, Miller NL, Uryu S, Lawson C, Jean C, Chen XL, Kleinschmidt EG, Schlaepfer DD. FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth. Breast Cancer Res. 2015; 17:47.
57. Guan JL, Shalloway D. Regulation of focal adhesionassociated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature. 1992; 358:690-692.
58. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras-and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest. 2009; 119:252-266.
59. Luo M, Fan H, Nagy T, Wei H, Wang C, Liu S, Wicha MS, Guan JL. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res. 2009; 69:466-474.
60. Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC, Muller WJ. Mammary epithelialspecific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci USA. 2007; 104:20302-20307.
61. Provenzano PP, Inman DR, Eliceiri KW, Beggs HE, Keely PJ. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol. 2008; 173:1551-1565.
62. Ribeiro A, Balasubramanian S, Hughes D, Vargo S, Powell EM, Leach JB. β1-Integrin cytoskeletal signaling regulates sensory neuron response to matrix dimensionality. Neuroscience. 2013; 248:67-78.
63. Perdiz D, Mackeh R, Pous C, Baillet A. The ins and outs of tubulin acetylation: more than just a post-translational modification? Cell Signal. 2010; 23:763-771.
64. Wloga D, Gaertig J. Post-translational modifications of microtubules. J Cell Sci. 2010; 123:3447-3455.
65. Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer. 2008; 99:689-694.
66. Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol. 2009; 41:199-213.
67. Bonezzi K, Belotti D, North BJ, Ghilardi C, Borsotti P, Resovi A, Ubezio P, Riva A, Giavazzi R, Verdin E, Taraboletti G. Inhibition of SIRT2 potentiates the antimotility activity of taxanes: implications for antineoplastic combination therapies. Neoplasia. 2012; 14:846-854.
68. Umezawa Y, Kurosu T, Akiyama H, Wu N, Nogami A, Nagao T, Miura O. Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells. Oncotarget. 2016; 7:44448-44461. doi: 10.18632/oncotarget.9844.
69. Liu F, Jia L, Wang P, Wang H, Farren TW, Agrawal SG. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia. Oncotarget. 2016; 7:32031-32045. doi: 10.18632/oncotarget.8672.
70. Srinivas KP, Viji R, Dan VM, Sajitha IS, Prakash R, Rahul PV, Santhoshkumar TR, Lakshmi S, Pillai MR. DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase. Oncotarget. 2016; 7:24154-24171. doi: 10.18632/ oncotarget.8131.
71. Cavalieri B, Mosca M, Ramadori P, Perrelli MG, De Simone L, Colotta F, Bertini R, Poli G, Cutrìn JC. Neutrophil recruitment in the reperfused-injured rat liver was effectively attenuated by repertaxin, a novel allosteric noncompetitive inhibitor of CXCL8 receptors: a therapeutic approach for the treatment of post-ischemic hepatic syndromes. Int J Immunopathol Pharmacol. 2005; 18:475-486.
72. La Rana G1, Russo R, D'Agostino G, Sasso O, Raso GM, Iacono A, Meli R, Piomelli D, Calignano A. AM404, an anandamide transport inhibitor, reduces plasma extravasation in a model of neuropathic pain in rat: role for cannabinoid receptors. Neuropharmacology. 2008; 54:521-529.
73. Choi Y, Yoon YW, Na HS, Kim SH, Chung JM. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 1994; 59:369-376.
74. Boland LM, Allen AC, Dingledine R. Inhibition by bradykinin of voltage-activated barium current in a rat dorsal root ganglion cell line: role of protein kinase C. J Neurosci. 1991; 11:1140-1149.
75. Platika D, Boulos MH, Baizer L, Fishman MC. Neuronal traits of clonal cell lines derived by fusion of dorsal root ganglia neurons with neuroblastoma cells. Proc Natl Acad Sci USA. 1985; 82:3499-3503.